top of page
NEWS
MARCH 21, 2024
RENATUS HAS BEEN GRANTED A US PATENT FOR CHRONIC KIDNEY DISEASE TREATMENT USING ITS PROPRIETARY CHOLESTEROL METABOLISM MODULATOR
Renatus Inc., a pharmaceutical company focused on developing cholesterol metabolism modulators, today announced the registration of a U.S. patent No. 11931376 entitled “METHODS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE.”
DECEMBER 26, 2023
RENATUS WAS INTRODUCED ON PAX ECONOMY TV
Renatus, a pharmaceutical company developing cholesterol modulators for the treatment of cholesterol-driven diseases, announced that it was introduced on Pax Economy TV's 'Close-Up of Business', which introduces promising small businesses based in South Korea.
NOVEMBER 22, 2023
RENATUS PRESENTED DATA ON RN-005, A CHOLESTEROL MODULATOR, IN PRECLINICAL CHRONIC KIDNEY DISEASE MODELS AT THE 2023 SCALE-UP CHALLENGE LAB CONFERENCE
Renatus presented data on RN-005, a cholesterol metabolism modulator, in preclinical chronic kidney disease models at the 2023 Scale-up Challenge Lab Conference.
bottom of page